1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Humira (adalimumab) is a recombinant, fully-human, IgG1 mAb that binds to TNFa and blocks its interaction with the p55 and p75 cell-surface receptors, which reduces inflammation and prevents tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the market for the treatment of RA.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Humira (Adalimumab) including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Humira (Adalimumab) for the top 9 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Humira (Adalimumab) performance.
- Obtain sales forecast for Humira (Adalimumab) from 2013-2023 in top 9 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia and China).

Table Of Contents

Humira (adalimumab) (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
4.1.4 Clinical Practice 33
5 Competitive Assessment 39
5.1 Overview 39
6 Humira (adalimumab) 41
6.1 Overview 41
6.2 Efficacy 43
6.3 Safety 43
6.4 SWOT Analysis 44
6.5 Forecast 44
7 Appendix 46
7.1 Bibliography 46
7.2 Abbreviations 50
7.3 Methodology 53
7.4 Forecasting Methodology 53
7.4.1 Diagnosed RA Patients 53
7.4.2 Percentage of Drug-Treated Patients 54
7.4.3 General Pricing Assumptions 54
7.4.4 Individual Drug Assumptions 55
7.4.5 Generic and Biosimilar Erosion 55
7.5 Primary Research - KOLs Interviewed for This Report 56
7.6 Primary Research - Prescriber Survey 58
7.7 About the Authors 59
7.7.1 Analyst 59
7.7.2 Reviewer 59
7.7.3 Therapy Area Director 60
7.7.4 Global Head of Healthcare 60
7.8 About GlobalData 61
7.9 Disclaimer 61

1.1 List of Tables

Table 1: Symptoms of RA 19
Table 2: 1987 ACR Diagnostic Criteria for RA 22
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 25
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 28
Table 6: EULAR 2013 Criteria for RA Remission 29
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 33
Table 8: Leading Branded Treatments for RA 2014 40
Table 9: Product Profile - Humira 42
Table 10: Humira SWOT Analysis, 2014 44
Table 11: Global Sales Forecasts ($m) for Humira, 2013-2023 45
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 58

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 29
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 30
Figure 5: Flowchart for the Management of RA - EULAR 2013 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.